Oligonucleotide-based therapeutics represent a transformative approach in modern biomedicine, enabling targeted modulation of gene expression, splicing, protein interactions, and immune activation. From antisense oligonucleotides to siRNA, these therapies are redefining […]
A Breakthrough in Post-Transcriptional Regulation Key Takeaways Introduction In the intricate “micro-city” of the cell, messenger RNA (mRNA) molecules function like delivery parcels, carrying genetic instructions from DNA to ribosomes […]
Step-by-Step Guide for Research Applications The rapid expansion of mRNA technology from vaccine development to gene editing, protein replacement, and cellular reprogramming has created an urgent need for small-scale, high-quality […]
Nature Breakthrough: mRNA Vaccines Extend Poly(A) Tails, Boosting mRNA Stability and Immune Response
mRNA vaccines have played a pivotal role in curbing the COVID-19 pandemic. However, mRNA molecules are inherently unstable and prone to degradation—a feature that, while beneficial for safety, can limit […]
Introduction Splice-switching oligonucleotides (SSOs) are a class of antisense oligonucleotides (ASOs) designed to modulate pre-mRNA splicing by redirecting the splicing machinery to alter exon inclusion or exclusion [1]. By binding to […]
Principle of Deuterated Drugs Deuterium is an isotope of hydrogen, where its atomic nucleus contains one additional neutron compared to hydrogen, giving it an atomic mass that is twice that […]
Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy, and next-generation ADCs are redefining the landscape by overcoming the limitations of earlier designs. These advancements span all three core […]
Traditional ADCs: The Need for Precision Over the past decade, all FDA-approved antibody-drug conjugates (ADCs) have been heterogeneous mixtures composed of monoclonal antibodies (mAbs) conjugated with varying numbers of cytotoxic drugs […]
Antibody-Drug Conjugates (ADCs) are a novel class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs. By precisely delivering chemotherapy […]
Proteolysis-targeting chimeras (PROTACs) and molecular glues have pioneered the targeted protein degradation (TPD) field and entered clinical evaluation. These small molecules utilize the ubiquitin-proteasome system to mediate intracellular protein degradation. In recent […]